Background: Interleukin-10 (IL10) signaling plays an important role in the pathogenesis of very early onset inflammatory bowel disease (VEO-IBD)
the small bowel, which is frequently involved in adolescent-and adult-onset IBD. Another difference is that VEO-IBD in children can be resistant to many of the standard medications. 4 ,5 Molecular analyses of rare Mendelian variants of IBD have identified candidate genes implicated in VEO-IBD. For example, monogenetic defects in the interleukin-10 (IL10), IL10 receptor (IL10R) subunit alpha (IL10RA), IL10R subunit beta (IL10RB), XIAP, and FOXP3 genes play important roles in VEO-IBD. 6 IL10, IL10RA, and IL10RB gene mutations have been associated with infant VEO-IBD accompanied by refractory diarrhea, perianal disease, frequent oral ulcers, skin folliculitis, sepsis, and other conditions. 7 Although several reports have examined defective IL10 signaling in patients with VEO-IBD, studies in Asian patients, especially Chinese patients, are lacking. In this study, our Chinese VEO-IBD Collaboration Group reported 42 VEO-IBD cases with confirmed defects in IL10 signaling. To the best of our knowledge, this is the first study to evaluate IL10 axis defects in a large number of Chinese patients with VEO-IBD.
MATERIALS AND METHODS
This study was approved by the Ethics Board at the Children's Hospital of Fudan University (Shanghai), and informed consent was obtained from each patient's parents. After exclusion of patients with infectious or allergic/eosinophilic gastrointestinal diseases, 93 patients with disease onset before the age of 2 years were recruited from 6 hospitals in the VEO-IBD Collaboration Group from March 1, 2015, through July 31, 2016. Forty-two of these patients were confirmed to have IL10 axis deficiencies, and all 93 patients had a confirmed diagnosis of IBD by endoscopy, radiology, laboratory testing, clinical evaluation, and genetic testing. The diagnosis of "VEO-IBD" was made according to the Porto criteria and the pediatric Paris modification of the Montreal classification. 8, 9 Available information from parents and siblings of the patients was also obtained for the study.
Clinical information was obtained from the medical records, and the following information was extracted: sex, first symptom and time of onset, clinical features, surgical history, medication history, and family history. After consent was obtained, blood samples were drawn from the study subjects.
Whole-exome Sequencing
Exome capture was accomplished using an Agilent SureSelect V4 kit, and sequencing was performed using an Illumina HiSeq 2000 platform. Whole-exome library preparation was based on modifications of a protocol that was completed using an Agilent SureSelect Human All Exon V5 Platform. Sequence read alignments were completed using Novoalign (V2.07.18) against the human reference genome GRCh37.p10 (http://www. novocraft.com). The major databases for known pathogenic and likely pathogenic mutations, i.e., ClinVar, OMIM, Human Gene Mutation Database (HGMD), Professional, and dbSNP, were used (see Supplementary material 1, Supplemental Digital Content 1, http://links.lww.com/IBD/B464). An immunodeficiency disease gene panel, including the  genes encoding IL10, IL10RA, and IL10RB, was designed to  analyze target genes (see Supplemental material 
Targeted Gene Panel

Sanger Sequencing
Sanger sequencing was performed to confirm the mutations in IL10RA and IL10RB using specific primers. The purified polymerase chain reaction products were sequenced using BigDye 3.0 (ABI) on a 3500 DNA Analyzer (Thermo Fisher). Sequencing data were analyzed using the sorting intolerant from tolerant (SIFT), Polyphen 2, and MutationTaster software for prediction scores.
IL-10RA Functional Analysis
Peripheral blood mononuclear cells were collected from patients and healthy controls for functional testing. The peripheral blood mononuclear cells were stimulated with IL-10 (50 ng/mL) or IL-6 (50 ng/mL). Cellular extracts were prepared after a standard protocol for western blotting. The membrane used for western blotting was read using a chemiluminescence system (GE Healthcare, United Kingdom). IL-6-induced p-STAT3 was used as an internal positive control.
Laboratory Testing, Elemental Nutrition, Treatment and Follow-up
Clinical parameters, including white blood cell count, platelet count, hemoglobin level, C-reactive protein level, erythrocyte sedimentation rate, serum albumin content, and prealbumin level, were determined for the patients enrolled in our collaboration group. The available height, weight, height Z score, and body weight Z score at the time of first diagnosis for each patient were calculated using the World Health Organization (WHO) Anthro (version 3.2.2). All the patients in this study underwent follow-up for treatment and prognostic information.
RESULTS
IL10, IL10RA, and IL10RB Genotypes
In this study, 42 patients with biallelic mutations affecting IL10R genes were identified among the 93 patients with VEO-IBD, representing 45.2% of the patient cohort. The 42 patients with IL10R mutations consisted of 22 males and 20 females. Forty-one patients had mutations in IL10RA, including 32 patients with compound heterozygous mutations and 9 with homozygous mutations; 1 patient had a homozygous mutation in IL10RB (Table 1) We also detected 1 novel homozygous mutation in IL10RB (c.737 G.A, p.W246X) in a consanguineous family. Two patients with heterozygote mutation for IL10RB gene were also detected (c.70C.A.p.P24T). The minor allele frequency values of the identified variants in the 1000 Genomes Project, EPS6500 and ExAC, are shown in Table 2 .
In the IL-10RA functioning test, the expression of p-STAT was observed in the patients and healthy controls after stimulation with IL-6, but it was not observed in the healthy controls without IL-6 stimulation. Of interest, in contrast to stimulation with IL-6, stimulation with IL-10 did not induce p-STAT expression in the patients (Fig. 1B) .
Characteristics of the Identified IL10R Mutations
All the IL10R mutation-affected children were of Han nationality and only 1 patient's parents were in a consanguineous marriage. The birth dates of the enrolled children ranged from 2010.7 to 2016.7. Regarding the first symptoms experienced by the patients, diarrhea and mouth ulcers were experienced in 88.1% (34 cases) and 23.8% (n ¼ 10) of patients, respectively. The time of onset of diarrhea and mouth ulcers were 10.4 6 8.0 days and 9.7 6 2.8 days, respectively. Furthermore, 41/42 patients had bloody stool; mouth ulcers were experienced by 23.8% (10 cases) of the patients, with a time of onset of 9.7 6 2.8 days. In total, 28.5% (12/42) of the patients had a family history of VEO-IBD that included sibling deaths due to similar symptoms (Table 3) . The extraintestinal manifestations in the patients included perianal abscesses (22/42), perianal fistulas (23/42), perianal skin tags (12/ 42), oral ulcers (20/42), recurrent eczema (15/42), and otitis media (1/42) ( Fig. 2A-D) .
Colonoscopies were performed on 32 of the children. The data describing colon or rectum involvement are shown in Table 3 .
Aphthous ulcerations and deep ulcerations in the intestinal mucosa were observed in the patients (Fig. 3A-D) . Radiological examination showed colon and rectum disease and skeletal changes (Fig. 4A-D) .
Laboratory Testing, Elemental Nutrition Evaluation, Responses to Therapy and Prognoses
The patients with IL10R mutations displayed increased white blood cell counts (mean 6 SD: 14. Twenty-five patients were treated with mesalazine, 24 patients were treated with thalidomide, 10 patients were treated with steroids, and 3 patients were treated with immunosuppressive agents. Eight patients underwent biological treatments, but 5 patients discontinued the therapy because of allergic reactions, and the remaining patients did not show any improvement in symptoms. In addition, 3 patients underwent fecal microbiota transplantation at other institutions before they enrolled in our study, and 16 patients underwent enterostomy because of intestinal perforation, intestinal obstruction, or intestinal fistula exclusion. Four patients underwent umbilical cord blood transplantation (UCBT). The patients were only transiently stable after all the above treatments except UCBT. After UCBT, the patients remained very stable and showed no gastrointestinal symptoms. The patients with IL10 receptor mutations showed retardation in the average height-for-age (23.2, [23.7, 21.6]) and weight-forage Z scores (22.8 6 2.0).
Follow-up revealed that 9 patients died of malnutrition, sepsis, and multiple organ failure. Among the 42 individuals, 31 were alive, and 30 were #6 years old at the time of drafting the manuscript. None of the patients developed lymphoma.
Comparisons of Mutations and Phenotypes with Those of Other Populations
We searched the literature from January 2009 to July 2016 in the PubMed and HGMD databases. The total number of IL10RA mutations that we found from this search was 28, with 21 
DISCUSSION
Glocker et al 7 were the first to report patients with IL10R signaling defects. To date, approximately 61 patients with VEO-IBD of various ethnicities have been shown to have IL10 pathway defects. 6, 7, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Most of these patients were of white, West Asian (e.g., Arabic) or South Asian ethnic groups, and the Arabic patients in particular had histories of family consanguinity. 24, 25 In this study, our collaboration group identified 42 VEO-IBD children with IL10R mutations, all of whom were of Han nationality. In general, these patients with IBD had homogenous clinical characteristics: (1) early onset refractory diarrhea and severe infectious diseases, (2) perianal diseases (abscess, fistula formation, fissure, tag) early in life with severe evolution in some cases, and (3) likely to have monogenic defects and resistant to traditional treatment. To the best of our knowledge, this is the first survey to report a large number of patients with IL10 signaling deficiencies.
In this study, we identified the c.301C.T (p.R101W) mutation in exon 3 and the c.537 G.A (p.T179T) mutation in exon 5 as most common mutations in the IL10RA gene in Chinese patients with VEO-IBD. Within East Asian populations, 16 infants with VEO-IBD and IL10RA mutations have been reported to date: 10 cases from Korea, 1 from Japan, 1 from Hong Kong, and 4 from the Chinese mainland. 16, 19, [21] [22] [23] 26 In these patients, c.301C.T (p.R101W) was the most common mutation, and no mutations in IL10RB or IL10 were reported. As noted above, a high proportion of our Chinese VEO-IBD cohort had the c.301C.T (p.R101W) mutation, which disturbs phosphorylation of IL10RA. Of interest, c.537 G.A (p.T179T) was another common mutation in our patients; only 3/16 patients from other Asian countries had this mutation. 19, 22, 23, 27 The c.537 G.A mutation caused an in-frame deletion of 18 bp in exon 4 of the IL10RA gene that leads to a loss of 6 amino acids (174-VPGNFT-179). We identified only 1 IL10RB mutation and also did not find mutations in IL10 in our patients, in contrast to reports from Western countries. Differences in the overall genetic make-up of humans from Western and Eastern regions of the world likely underlie the differences observed here. Furthermore, in our study, most of the children with VEO-IBD and IL10RA mutations were compound heterozygous, as they were born to nonconsanguineous families. In contrast to our findings, IL10 signaling pathway deficiencies have been found in patients with VEO-IBD from North America and Europe who were born to consanguineous marriages; as such, homozygous mutations were the most common IL10R mutations in these individuals. 12 Individuals from Eastern regions of the world are ethnically distinct from those in European and North American countries. The high consanguinity rate in the Arabic population resulted in a high incidence of homozygous mutations in IL10R and the associated prevalence of VEO-IBD. 28 In this study, we only identified 1 IL10RB homozygous mutation (Exon 6: c.737 G.A, p.W246X). This may be because IL10 and IL10RB are not the major genes associated with IL10 signaling deficiencies in Eastern populations, especially Chinese infants with VEO-IBD.
Kotlarz et al. 12 reported that 16 of 66 (24.2%) patients with early onset IBD (defined as an age of onset ,5 years) had mutations in the IL-10 pathway. Beser et al 20 identified mutations affecting the IL-10 pathway in 3 of 17 (17.6%) patients with a diagnosis of very early onset IBD (defined as an age of onset ,6 years). In a more recent study from Korea, genetic testing revealed that 7 of 40 patients (17%) had IL10RA mutations among patients IBD less than 10 years of age. 16 In our study, we found that among 93 patients with early onset IBD (age of onset ,2 years), 42 (45.2%) had IL10R mutations. This high percentage of IL10R mutations might be due to 2 factors. First, the patients who we recruited were infants with IBD aged 2 years old, and monogenic mutations were more likely to occur. Second, our department had performed UCBT successfully in a 6-monthold infant with an IL10RA mutation in 2015. 29 This was the first UCBT for VEO-IBD in China, and the infant recovered very well. Therefore, many infantile patients with IBD with similar phenotypes are brought to our department for diagnosis and treatment, providing us with many opportunities to collect data.
Cases of VEO-IBD during the first year of life likely reflect monogenic defects in pathways that control intestinal homeostasis, such as the IL10 signaling cascade. 30 IL10 and IL10R deficiencies can cause immunodeficiencies that result in severe dysfunctions in the immune system, especially in the intestine. 31 The affected patients displayed IBD-like symptoms accompanied by severe perianal disease in early life.
The clinical characteristics of the children with IL10R mutations were analyzed. These patients all showed symptoms within the first year of life, with onset of refractory diarrhea or recurrent oral ulcers being the first syndromes to emerge. In addition, these patients were likely to have perianal diseases, such as perianal skin tags, abscesses, fissures, and fistulas. In this study, 41 children with VEO-IBD had IL10RA mutations, and only 4 of these children did not suffer from perianal disease. Thus, perianal disease was not fully penetrant as a symptom. Patient 16 did not display the symptom of diarrhea; however, he had repeat oral ulcers and electrolyte disturbance. Children who have repeated oral ulcers as their first syndrome should undergo further screening for IBD. In this study, 12 children had a family history of IBD that included their siblings dying from similar symptoms. Therefore, pediatric gastroenterologists should be aware of and recognize monogenic disorders with underlying immunodeficiency in patients with VEO-IBD to avoid misdiagnosing these patients with conventional IBD.
An interesting finding from this study is that patients with VEO-IBD who had IL10R mutations were resistant to the conventional therapies used for IBD. The effects of mesalazine, thalidomide, steroids, immunosuppressive agents, and biological agents were limited. These treatments were consistent with the reports from Western countries. 20, 32 Although fecal microbiota transplantation has been reported to have impressive effects in adult patients with IBD, 33 it produced no benefit in our patients: 1 patient using this therapy died, and 2 others had to undergo enterostomy. In our study, 4 patients underwent hematopoietic stem cell transplantation and showed impressive effects. These results suggest that hematopoietic stem cell transplantation is the best therapeutic option for patients suffering from IL10/IL10R deficiencies, and that this therapy should be completed as early as possible.
With improvements in biotechnology, the monogenic immunodeficiencies caused by VEO-IBD have become increasingly recognized by pediatric gastroenterologists. 34 Patients with VEO-IBD who are immunodeficient show resistance to conventional therapy and have a higher mortality rate. In our study, 9 patients with IL10R-mutated VEO-IBD (21.4%) died because of failure to thrive and systematic sepsis.
There are several limitations in this study. One limitation was that the data of VEO-IBD population of general and pediatric IBD in China were not yet available, but we are planning to conduct some epidemiological investigations to complete the part. In addition, we were unable to provide a general estimate of mortality due to VEO-IBD in the Han population because of the insufficient data availability. Another limitation is that several patients died before their clinical information was complete; colonoscopy information of some patients was not available because they underwent enterectomy or manifested enterostenosis before evaluation.
In conclusion, we found that the c.301 C.T (p.R101W) and c.537 G.A (p.T179T) mutations of IL10RA were the most common IL10R mutations in Chinese patients with VEO-IBD. These patients had growth and development delays, intestinal diseases, and a high risk of death. For such patients, further follow-up should be performed to assess growth, development, treatment, and prognosis. Furthermore, patients with VEO-IBD with IL10 signaling deficiencies in different geographical regions and of different races should be investigated.
